Table 4.
Clinical and pathological characteristics of four distinct molecular subgroups stratified by biopsy (Bx) and fusion (Fx) status
| Clinical parameters1 | Bx(+)/Fx(−) | Bx(+)/Fx(+) | Bx(−)/Fx(+) | Bx(−)/Fx(−) |
| No. of cases (n) | 18 | 21 | 11 | 42 |
| Age | 69.50 (54–86) | 68 (50–81) | 75.00 (65–83)*** | 66 (52–87) |
| Pre-Bx prostate-specific antigen (ng/mL) | 6.60 (2.33–271.57) | 6.71 (1.18–54.46) | 7.51 (1.29–25.25) | 5.83 (0.74–14.31) |
| Prostate Size (cc) | 35.00 (19–110) | 35 (16–88) | 46 (19–80) | 46.50 (9–145) |
| Prostate-specific antigen density | 0.21 (0.05–4.24)** | 0.18 (0.05–1.88)* | 0.15 (0.05–0.63) | 0.12 (0.03–0.56) |
| HG PIN (n)2 | 8 | 9 | 6* | 10 |
| HG PIN core no. >2 (n)2 | 4 | 7 | 4* | 6 |
| Gleason score | 6 (6–9) | 6 (6–9) | – | – |
| No. of cores with cancer | 3 (1–10) | 3 (1–10) | – | – |
| Max% inv. of single core | 40 (5–100) | 40 (5–100) | – | – |
| Treatment (n)3 | 4 RP3 | 5 RP | – | – |
PIN, prostatic intraepithelial neoplasia.
1
Expressed as median with min–max values unless indicated differently, Mann–Whitney test (vs. Bx(−)/Fx(−) where applicable; *P <0.05, **P <0.01, ***P <0.001).
2
Number of cases, chi-square test (P <0.05).
3
Radical prostatectomy.